Completed PHASE2 INTERVENTIONAL 3-arm NCT01253603

Efficacy, Safety, and Pharmacokinetics of QAW039

A Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Pharmacokinetics of QAW039 in Steroid-free Patients With Mild to Moderate Persistent Asthma

Sponsor: Novartis Pharmaceuticals

Conditions Persistent Asthma

Interventions Fluticasone propionate inhaler twice daily for 28 days Placebo to QAW039 capsules once daily for 28 days QAW039 capsules once daily for 28 days

Updated 9 times since 2017 Last updated: Dec 11, 2020 Started: Nov 30, 2010 Primary completion: Sep 30, 2011 Completion: Sep 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01253603, this PHASE2 trial focuses on Persistent Asthma and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 9 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Oct 2020 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Oct 2020 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Nov 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bellevue, United States , Berlin, Germany , Berlin, United States , Bucharest, Romania , Cologne, Germany , Dallas, United States , Encinitas, United States , Frankfurt, Germany , Hamburg, Germany , Huntington Beach, United States and 14 more locations